The Federal Circuit affirmed the decision of the Patent Trial and Appeal Board that challenged claims of DexCom Inc.'s patent that discloses a transcutaneous continuous glucose sensor system are unpatentable as obvious over prior art, in an inter partes review by Abbott Diabetes Care Inc. According to the court, the board’s obviousness conclusion is supported by substantial evidence.
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.